An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
via Google News
The Latest on: Parkinson’s disease
- Paul Sinha health: ‘I don’t consider myself unlucky’ Sinnerman discusses his Parkinson’son January 23, 2021 at 12:01 pm
PAUL SINHA made a name for himself playing one of the quizzes on popular television show The Chase. Two years ago, his world came crashing down when he was diagnosed with Parkinson's disease.
- Parkinson’s meds are hard to grab, so TikTok users crowdsourced a solutionon January 23, 2021 at 6:00 am
That video set off a domino effect, inspiring designers, engineers, and hobbyists across TikTok to craft a better pill bottle for people with tremors or other motor disorders. The video made its way ...
- After Parkinson’s diagnosis, guitarist learns to play againon January 23, 2021 at 12:12 am
The Norfolk guitarist marked the end of 2020 by playing a three-hour set at Black Cow Fat Pig, his first performance in front of a crowd in about a year. “There’s always a little bit of nerves when ...
- TikTok Users Rallied to Design a Better Pill Bottle for People With Parkinson’son January 22, 2021 at 9:00 am
TikTok users have rallied to 3D-print better pill bottles that are easily usable by people with shaky hands, such as those with Parkison's.
- Parkinson's Foundation Announces COVID-19 Survey Resultson January 22, 2021 at 5:52 am
Disclaimer | Commerce Policy | Made In NYC | Stock quotes by finanzen.net MIAMI and NEW YORK, Jan. 21, 2021 /PRNewswire/ -- The Parkinson's Foundation today announced the results of a survey ...
- Global Parkinson's Disease (PD) Drugs Market Research During 2020-2024 | Industry Impact Analysis Due to COVID-19 Spread | Technavioon January 21, 2021 at 11:38 pm
The Parkinson's disease (PD) drugs market is poised to grow by USD 1.57 billion during 2020-2024 progressing at a CAGR of almost 6% during the forecast period. Worried about the impact of COVID-19 on ...
- Study examines association between gut mycobiome and Parkinson’s diseaseon January 21, 2021 at 10:11 am
The bacterial gut microbiome is strongly associated with Parkinson's disease (PD), but no studies had previously investigated he role of fungi in the gut.
- Study suggests that gut fungi are not associated with Parkinson's diseaseon January 21, 2021 at 9:14 am
The bacterial gut microbiome is strongly associated with Parkinson's disease (PD), but no studies had previously investigated he role of fungi in the gut. In this novel study published in the Journal ...
- New Parkinson's disease therapeutics discoveredon January 20, 2021 at 4:38 am
Gurion University of the Negev researchers have discovered that the protein BMP5/7 offers promising therapeutics that could slow down or halt the progression of Parkinson's disease. The findings were ...
- BMP5/7 protein offers promising therapeutics that could halt the progression of Parkinson's diseaseon January 19, 2021 at 10:39 pm
Gurion University of the Negev researchers have discovered that the protein BMP5/7 offers promising therapeutics that could slow down or halt the progression of Parkinson's disease.
via Bing News